Single-dose subcutaneous administration of recombinant human parathyroid hormone [rhPTH(1-84)] in healthy postmenopausal volunteers

Clinical Pharmacology and Therapeutics

Volumn 61, Issue 3, 1997, Pages 360-376

  Schwietert, Hendrik Reinier ^a   Groen, Edwin W J ^a   Sollie, Frans A E ^a   Jonkman, Jan H G ^a  

^a PRA International USA   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; PARATHYROID HORMONE; PLACEBO;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PHARMACODYNAMICS; PHARMACOKINETICS; POSTMENOPAUSE; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; VOLUNTEER;

ADULT; AMINO ACIDS; AREA UNDER CURVE; CALCIUM; CREATININE; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HALF-LIFE; HUMANS; INJECTIONS, SUBCUTANEOUS; PARATHYROID HORMONE; POSTMENOPAUSE; RECOMBINANT PROTEINS; REFERENCE VALUES;

EID: 0030897225     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(97)90169-7     Document Type: Article

References (16)

1. Van Doom L, Lips P, Netelenbos JC, Hackeng WHL. Bone histomorphometry and serum concentrations of intact parathyroid hormone [PTH(1-84)] in patients with primary hyperparathyroidism. Bone Miner 1993; 23:233-42.
2. Markowitz ME, Arnaud S, Rosen JF, Thorpy M, Laximinarayan S. Temporal interrelationships between the circadian rhythms of serum parathyroid hormone and calcium concentrations. J Clin Endocrinol Metab 1988;67:1068-73.
3. Dempster DW, Cosman F, Parisien M. Shen V. Anabolic actions of parathyroid hormone on bone. Endocr Rev 1993;14:690-709.
4. Mosekilde L, Sogaard CH, Danielsen CC, Torring O, Nilsson MHL. The anabolic effects of human parathyroid hormone (hPTH) on rat vertebral body mass are also reflected in the quality of bone, assessed by biomechanical testing: a comparison study between hPTH-(1-34) and hPTH-(1-84). Endocrinology 1991; 129:421-8.
5. Kimmel DB, Bozzato RP, Kronis KA, Coble T, Sindrey D, Kwong P, et al. The effect of recombinant human (1-84) or synthetic human (1-34) parathyroid hormone on the skeleton of adult osteopenic ovariectomized rats. Endocrinology 1993;132:1577-84.
6. Ejersted C, Andreassen TT, Oxlund H, Jorgensen PH, Bak B, Häggblad J, et al. Human parathyroid hormone (1-34) and (1-84) increase the mechanical strength and thickness of cortical bone in rats. J Bone Miner Res 1991;8:1097-101.
7. Finkelstein JS, Klibanski A, Schaefer EH, Hornstein MD, Schiff I, Neer RM. Parathyroid hormone for the prevention of bone loss induced by oestrogen deficiency. N Engl J Med 1994;331:1618-23.
8. Gasser JA. Current treatments and future opportunities. In: Russel RG, editor. Bone disease and osteoporosis. London: IBC Technical Services, 1994:169.
9. Whitfield JF, Morley P. Small bone-building fragments of parathyroid hormone: new therapeutic agents for osteoporosis. Trends Pharmacol Sci 1995; 16:382-5.
10. Hesch RD, Busch U, Prokop M, Delling G, Rittinghaus EF. Increase of vertebral density by combination therapy with pulsatile 1-3ShPTH and sequential addition of calcitonin nasal spray in osteoporotic patients. Calcif Tissue Int 1989;44:176-80.
11. Hodsman AB, Steer BM, Fraher LJ, Drost DJ. Bone densitometric and histomorphometric responses to sequential human parathyroid hormone (1-38) and salmon calcitonin in osteoporotic patients. Bone Miner 1991;14:67-83.
12. Eyre DR, Koob TJ, Vanness KP. Quantitation of hydroxypyridinium cross-links in collagen by high performance liquid chromatography. Anal Biochem 1984;137:380-8.
13. Holick MF, Krane SM, Potts JT. Calcium phosphorus, and bone metabolism: calcium-regulating hormones. In: Isselbacher KJ, Braunwald E, Wilson JD, et al., editors. Harrison's principles of internal medicine. 13th ed. New York: McGraw-Hill, 1994:2137-87.
14. Uebelhart D, Gineyts E, Chapuy MC, Delmas PD. Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. Bone Miner 1990;8:87-96.
15. Cosman F, Shen V, Herrington B, Lindsay R. Response of the parathyroid gland to infusion of human parathyroid hormone (1-34) [PTH-(1-34)]: demonstration of suppression of endogenous secretion using immunoradiometric intact PTH (1-84) assay. J Clin Endocrinol Metab 1993;73:1345-51.
16. Lindsay R, Nieves J, Henneman E, Shen V, Cosman F. Subcutaneous administration of the aminoterminal fragment of human parathyroid hormone (1-34): kinetics and biochemical response in oestrogenized osteoporotic patients. J Clin Endocrinol Metab 1993;77:1535-9.